Visiongain Publishes Plasma Protein Therapeutic Market Report 2020-2030

30 July 2020
Pharma

Visiongain has launched a new report Plasma Protein Therapeutic Market Report 2020-2030: Forecasts by Product (Albumin, Immunoglobulin, Alpha-1 Proteinase Inhibitor, Coagulation Factors), by Application (Hemophilia, Primary Immunodeficiency Disorder, Idiopathic Thrombocytopenic Purpura, Others), and by Region (North America, Europe, Asia Pacific, Latin America & MEA), Including Forecasts by Major Developed Countries and Developing Countries, Plus Profiles of Leading Companies.

Plasma is a protein-rich fluid and 90% of it is made of water. Some of the functions of plasma proteins are clotting of blood, transport of various biochemical components in the circulatory systems and immunity against diseases. Different types of diseases such as neurological, autoimmune, and autoimmune diseases can be treated by isolating proteins from plasma. In this type of therapeutics, the deficient or missing type of protein is replaced using plasma protein. Infusion and injecting these plasma proteins can also be used to chronic and genetic diseases.

The increase in the use of plasma protein in the pharmaceutical industry for the treatment of various blood disorders and autoimmune diseases is the major factor boosting the demand for plasma protein therapeutics. Plasma proteins can be used as replacement therapies to treat different blood conditions such as dysfibrinogenemia, deficiency of a coagulation factor, and afibrinogenemia. Moreover, the technological advancements, increase in disposable income globally, and availability of favourable reimbursements helps to drive the market growth. Technological advancement to improve the efficacy of plasma proteins and enhancing the technique of sample plasma extraction will further increase the demand for plasma proteins therapy.

The increase in geriatric population, optimization of downstream process, and increasing number of applications further drives the growth of global plasma protein therapeutic market. As per the data by WHO, the geriatric population is expected to increase to 16% of the global population by 2050 as compared to 7% of the global population that were above 65 years in 2000. As the elderly population are more prone to suffer from cardiovascular and neurological diseases, the increase in elderly population will increase the demand for plasma protein therapeutics. Plasma proteins are increasing being used for the treatment of various other disease such as sepsis, myasthenia gravis, malaria, and Alzheimer’s disease. However, the issues related to manufacturing and storage in developing countries and slow approval process are expected to hamper the market growth.

The Visiongain report analyst commented “the increase in use of plasma protein as biotherapeutics, increase in R&D activities to use plasma proteins for number of applications, and high demand for advanced therapeutics are the major driving factors for growth of the plasma protein therapeutic market”.

The report covers a detailed competitive outlook that includes market share and company profiles of key players operating in the global market. Key players profiled in the report include CSL Behring LLC, Baxter International, China Biologics, Octapharma AG, Grifols S.A., Shire Plc, Bayer AG, Biotest AG, and Kedrion S.P.A.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Single-Cell Analysis Market Report 2022-2032

The global single cell analysis market was valued at US$3,255.0 million in 2022 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.

26 May 2022

Read

Visiongain Publishes Ophthalmic Devices Market Report 2022-2032

The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.

19 April 2022

Read

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2022-2032

The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet

13 April 2022

Read

Visiongain Publishes Pharmaceutical Contract Manufacturing Market Report 2022-2032

The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.

13 April 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever